← Back to the wire

Replimune Wins FDA Approval For Melanoma Drug After Two Previous Rejections

Product·2 articles across 2 outlets

Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data

The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.

The accelerated clearance follows two earlier rejections and the support of patient advocates.

Replimune

Sources

Every quote below is verbatim from the article it is attributed to.

SourceReports the news
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.